Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'Distribution Information' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Distribution Information' found in 0 term [] and 23 definitions []
1 - 5 (of 23)     next
Result Pages : [1 2 3 4 5]
MRI Resources 
MRCP - Spectroscopy - Knee MRI - Functional MRI - Image Quality - Universities
 
ABLAVAR™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.

Drug Information and Specification
NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
DEVELOPER EPIX Pharmaceuticals, Inc.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY 20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC Intravascular
OSMOLALITY 825 mOsmol/kg H2O
CONCENTRATION 244 mg/mL, 0.25mmol/mL
DOSAGE 0.12 mL/kg, 0.03 mmol/kg
PREPARATION ready to use
INDICATION Contrast enhanced magnetic resonance angiography
DEVELOPMENT STAGE FDA approved
DISTRIBUTOR See below
PRESENTATION 10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Vasovist® Approved ?
USA, Canada, Australia ABLAVAR™ Approved Lantheus Medical Imaging, Inc.

spacer
 
• Share the entry 'ABLAVAR™':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'ABLAVAR™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
MRI Resources 
Distributors - Open Directory Project - Libraries - Journals - Mobile MRI - Nerve Stimulator
 
Artirem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200). Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.

Drug Information and Specification
NAME OF COMPOUND Gadoterate meglumine, Gd-DOTA
DEVELOPER Guerbet S.A.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
CONCENTRATION 0,0025 mmol/ml
PREPARATION Finished product
INDICATION Arthrography
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Pre-filled syringes of 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Dotarem® for sale Guerbet S.A.
France, Switzerland Artirem® for sale Guerbet S.A.
Australia Dotarem® for sale

spacer

• View the DATABASE results for 'Artirem®' (4).Open this link in a new window

MRI Resources 
Mass Spectrometry - General - Crystallography - Claustrophobia - MR Guided Interventions - Sequences
 
Dotarem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

Drug Information and Specification
NAME OF COMPOUND Gadoterate meglumine, Gd-DOTA
DEVELOPER Guerbet S.A.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1350 mosm/kgH2O
CONCENTRATION 0.5 mol/L
DOSAGE 0.1 mmol/kg / 0.2mL/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Dotarem® for sale Guerbet S.A.
France, Switzerland Artirem® for sale Guerbet S.A.
Australia Dotarem® for sale

spacer

• View the DATABASE results for 'Dotarem®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
  News & More:
Guerbet to Exhibit Recently U.S. Approved Imaging Agents at 100 Year Anniversary of RSNA
Thursday, 13 November 2014   by money.cnn.com    
MRI Resources 
Online Books - Intraoperative MRI - Non-English - - Artifacts - MR Guided Interventions
 
Endorem™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
A brand name for ferumoxide (same as Feridex®)
Endorem™ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endorem™ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
See also Ferumoxide.

Drug Information and Specification
NAME OF COMPOUND Dextran-coated ferumoxide, Ami-25
DEVELOPER AMAG Pharmaceuticals, Inc., Guerbet S.A.
CENTRAL MOIETY Fe2+/Fe3+
CONTRAST EFFECT T2, predominantly negative enhancement
RELAXIVITY r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC RES-directed
OSMOLALITY 340 mosm/kgH2O
CONCENTRATION 11.2mg Fe/ml
DOSAGE 15 µmol Fe/kg
PREPARATION Suspend in an isotonic glucose solution
INDICATION Liver
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Feridex I.V. for sale Bayer HealthCare Pharmaceuticals
Japan Feridex® for sale Eiken Chemical Co., Ltd.
EU
Brazil
Endorem™ for sale Guerbet S.A.
Argentina Feridex I.V. for sale Temis-Lostaló
South Korea Feridex I.V. for sale TaeJoon Pharmaceuticals
Israel Feridex I.V. for sale Discotrade
China Feridex I.V. for sale Pharmagenesis, Inc.

spacer

• View the DATABASE results for 'Endorem™' (5).Open this link in a new window

 
Further Reading:
  News & More:
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
Stimulator pool - Safety Products - MRI Technician and Technologist Jobs - Health - Safety Training - Directories
 
Eovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Eovist® (other brand name Primovist™) is a organ specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans. Excretion of Gd-EOB-DTPA in the bile may also permit visualization of both the gall bladder and the bile ducts.
Eovist® brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic and accumulation phase imaging can also be performed after bolus injection of Eovist®. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma at 10 to 20 minutes after injection. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.
WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Drug Development and Approval Process USA, Contrast Medium, Hepatobiliary Contrast Agents, Tumor Specific Agents and Molecular Imaging.


Drug Information and Specification
NAME OF COMPOUND Gadoxetic acid disodium, Gd-EOB-DTPA
DEVELOPER Bayer Schering Pharma AG
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY Short T1-relaxation time
PHARMACOKINETIC 50% hepatobiliary, 50% renal excretion
OSMOLALITY 884 mosm/kgH2O
CONCENTRATION 0.25 mol/L
DOSAGE 12,5 - 25 µmol/kg
PREPARATION Finished product
INDICATION Liver lesions
DEVELOPMENT STAGE for sale
DISTRIBUTOR See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada Eovist® for sale Bayer HealthCare Pharmaceuticals
EU Primovist™ for sale Bayer Schering Pharma AG

spacer

• View the DATABASE results for 'Eovist®' (4).Open this link in a new window

 
Further Reading:
  Basics:
HIGHLIGHTS OF PRESCRIBING INFORMATION
2008   by berlex.bayerhealthcare.com    
MRI Resources 
Pacemaker - RIS - PACS - Safety Products - Open Directory Project - Online Books
 
     1 - 5 (of 23)     next
Result Pages : [1 2 3 4 5]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



The impact of TTIP/TPP on the MRI scanner market will bring :
more variety 
better scanners 
more risk 
less regulation 
cheaper scanners 
Lost in Translation 
no change at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2016 SoftWays. All rights reserved. [ 26 February 2017]
Terms of Use | Privacy Policy | Advertising
 [last update: 2017-02-21 00:45:00]